Evogene Receives Formal Nasdaq Delisting Notice for Bid Price Deficiency, Faces September Deadline

summarizeSummary

Evogene Ltd. received a formal notice from Nasdaq regarding its non-compliance with the minimum bid price rule, initiating a 180-day period to regain compliance and avoid delisting.

check_boxKey Events

• Nasdaq Bid Price Deficiency Notice

  Evogene Ltd. received a letter from Nasdaq notifying it of non-compliance with Listing Rule 5550(a)(2), as its ordinary shares have traded below $1.00 for 30 consecutive business days.

• 180-Day Compliance Period Granted

  The company has until September 28, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

• Reverse Stock Split Under Consideration

  Evogene intends to consider a reverse stock split, among other alternatives, to cure the deficiency and regain compliance with the minimum bid requirement.

• Follows Prior Delisting and Going Concern Disclosures

  This formal notice follows a 20-F filing on March 26, 2026, which disclosed substantial doubt about the company's going concern and mentioned imminent Nasdaq delisting, though this 6-K clarifies a specific compliance period.

auto_awesomeAnalysis

Evogene Ltd. has received a formal notification from Nasdaq regarding its non-compliance with the minimum bid price rule, as its shares have traded below $1.00 for 30 consecutive business days. This is a critical development for the micro-cap company, which recently disclosed substantial doubt about its ability to continue as a going concern in its 20-F filing on March 26, 2026. While the company has been granted a 180-day compliance period until September 28, 2026, and is considering a reverse stock split, the formal notice adds significant pressure. Maintaining a Nasdaq listing is crucial for investor confidence and access to capital, especially given the prior F-3 filing indicating a major shareholder's intent to sell shares. Failure to regain compliance could lead to delisting and a move to less liquid over-the-counter markets.